Abstract
Induction of apoptosis in cancer cells with chemotherapy and radiation treatment is a major strategy in cancer therapy at present. Nevertheless, innate or acquired resistance has been an obstacle for conventional clinical therapy. TNF-related apoptosis inducing ligand (TRAIL / Apo-2L) is a typical member of the TNF ligand family that induces apoptosis through activating the death receptors. In recent years, considerable attention has been focused on the potential benefits of TRAIL in cancer therapy, as the majority of cancer cells are sensitive to TRAIL-induced apoptosis, while most normal cells are TRAIL-resistant. Furthermore, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects. In this review, we will discuss the regulation mechanism of TRAIL-induced apoptosis and the molecular basis of the synergies created by its use in combination with chemotherapeutic agents and irradiation. We also analyze in detail that TRAIL may be cytotoxic, as this is a potential obstacle to its development for being used in cancer therapy.
Keywords: trail, cancer therapy, tnf-related apoptosis inducing ligand, tnf ligand family, death receptors, trail-resistant
Current Molecular Medicine
Title: TRAIL: A Potential Agent for Cancer Therapy
Volume: 3 Issue: 8
Author(s): Juan Shi, Dexian Zheng, Kwan Man, Sheung-tat Fan and Ruian Xu
Affiliation:
Keywords: trail, cancer therapy, tnf-related apoptosis inducing ligand, tnf ligand family, death receptors, trail-resistant
Abstract: Induction of apoptosis in cancer cells with chemotherapy and radiation treatment is a major strategy in cancer therapy at present. Nevertheless, innate or acquired resistance has been an obstacle for conventional clinical therapy. TNF-related apoptosis inducing ligand (TRAIL / Apo-2L) is a typical member of the TNF ligand family that induces apoptosis through activating the death receptors. In recent years, considerable attention has been focused on the potential benefits of TRAIL in cancer therapy, as the majority of cancer cells are sensitive to TRAIL-induced apoptosis, while most normal cells are TRAIL-resistant. Furthermore, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects. In this review, we will discuss the regulation mechanism of TRAIL-induced apoptosis and the molecular basis of the synergies created by its use in combination with chemotherapeutic agents and irradiation. We also analyze in detail that TRAIL may be cytotoxic, as this is a potential obstacle to its development for being used in cancer therapy.
Export Options
About this article
Cite this article as:
Shi Juan, Zheng Dexian, Man Kwan, Fan Sheung-tat and Xu Ruian, TRAIL: A Potential Agent for Cancer Therapy, Current Molecular Medicine 2003; 3 (8) . https://dx.doi.org/10.2174/1566524033479401
DOI https://dx.doi.org/10.2174/1566524033479401 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Apoptosis is a Critical Cellular Event in Cancer Chemoprevention and Chemotherapy by Selenium Compounds
Current Cancer Drug Targets Novel Inhibitors of Inosine Monophosphate Dehydrogenase in Patent Literature of the Last Decade
Recent Patents on Anti-Cancer Drug Discovery A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Current Cancer Drug Targets Hyaluronic Acid as a Protein Polymeric Carrier: An Overview and a Report on Human Growth Hormone
Current Drug Targets Separation of Ginseng Active Ingredients and their Roles in Cancer Metastasis Supplementary Therapy
Current Drug Metabolism Oleuropein Mediated Targeting of Signaling Network in Cancer
Current Topics in Medicinal Chemistry Phosphine-Gold(I) Compounds as Anticancer Agents: General Description and Mechanisms of Action
Anti-Cancer Agents in Medicinal Chemistry Overview on Inhalable Nanocarriers for Respiratory Immunization
Current Pharmaceutical Design Cannabinoids, Immune System and Cytokine Network
Current Pharmaceutical Design Proteomics Using Mammospheres as a Model System to Identify Proteins Deregulated in Breast Cancer Stem Cells
Current Molecular Medicine Patenting the Gene-Hubs of Endoplasmic Reticulum Stress: The Systems Biology Approach
Recent Patents on Biotechnology The Role of Glioma Microenvironment in Immune Modulation: Potential Targets for Intervention
Letters in Drug Design & Discovery Laparoscopic Reconstructive Surgery in Pediatric Urology: An Overview of Current Options
Current Pediatric Reviews Glioma: Tryptophan Catabolite and Melatoninergic Pathways Link microRNA, 14-3- 3, Chromosome 4q35, Epigenetic Processes and other Glioma Biochemical Changes
Current Pharmaceutical Design Molecular Imaging of Breast Cancer: Role of RGD Peptides
Mini-Reviews in Medicinal Chemistry The Potential of Ellagic Acid as a Possible Antimalarial Drug Candidate
Current Bioactive Compounds The Role of Synovial Fibroblasts in Mediating Joint Destruction in Rheumatoid Arthritis
Current Pharmaceutical Design Regulation of Death and Growth Signals at the Plasma Membrane by Sphingomyelin Synthesis: Implications for Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Melanin-Concentrating Hormone as a Metabolic and Cognitive Regulatory Factor
Current Medicinal Chemistry - Central Nervous System Agents ATP Synthesis Revisited: New Avenues for the Management of Mitochondrial Diseases
Current Pharmaceutical Design